AMCOR reports its Q3 2026 results on May 6, with the packaging giant nursing a 5% price decline over the past month and an analyst community that has grown noticeably more cautious heading into the release.
The price tells the clearest setup story. AMCR closed at $37.75 on May 1, down 3.1% on the week and off 9.5% year-to-date. The RSI14 has fallen to 37 — approaching oversold territory without yet triggering it. That weakness has attracted incrementally more short interest: short positions climbed nearly 30% over the past month to 1.6% of the free float. At this level, short interest is modest rather than alarming, and the lending market confirms there is no squeeze dynamic. Borrow costs are running at just 0.50%, and availability remains well supplied, meaning new shorts face no meaningful friction entering the position. Options sentiment is similarly understated — the put/call ratio is 0.54, only marginally above its 20-day average of 0.49, placing the z-score at a benign 0.54. Hedging demand is present but not elevated.
The analyst debate is where the real tension lies. The consensus remains a buy, with a mean price target around $50 — implying 33% upside from current levels. Yet that headline rating masks a diverging trend on the Street. Wells Fargo downgraded to Equal-Weight in March, cutting its target to $43. Truist maintained its Buy but lopped $10 off its target to $50 in mid-April. Deutsche Bank initiated coverage with a Buy and a $50 target at the start of April — a constructive signal but one that lands at the same level competitors are cutting to. The direction of travel is cooler, even if the formal ratings haven't collapsed. Bulls point to a forward yield approaching 7% and an EV/EBITDA multiple of 8.4x — undemanding for a company with roughly $23bn in estimated revenues and nearly $2.6bn in operating cash flow. Bears counter that the earnings momentum scores are soft: EPS momentum ranks in the 35th percentile over 90 days, and EPS surprise history places near the 30th percentile, suggesting Amcor has not been reliably beating.
The most notable institutional move heading in is a large addition by Charles Schwab Investment Management, which reported adding over 67 million shares in its latest filing — lifting its reported stake to more than 18% of shares. Whether that reflects index rebalancing or active conviction is unclear from the data, but the scale of the addition is visible. Peer packaging names showed a mixed week: BALL and GEF closed fractionally higher, while ATR fell nearly 4% on the week, suggesting sector headwinds are uneven. Earnings history adds one data point worth noting: the most recent comparable print produced a one-day move of around plus 4%, with the five-day follow-through extending to over 11%.
May 6's print will test whether the structural free cash flow and dividend story — the core of the bull case — holds up against softening EPS momentum and a macro backdrop that has already trimmed the stock to multi-month lows.
See the live data behind this article on ORTEX.
Open AMCR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
